Five-fold increase of OS at 5 years with nivolumab vs docetaxel Presented ByProf. Scott Gettinger, Yale Cancer Center, USA TrialCheckMate 017, CheckMate 057 ConferenceWCLC 2019 8 November, 2019 23:00